Celcuity : Science Day Presentation

Celcuity Science Day

Unlocking the Potential of Treating Cancers with

PI3K/mTOR Involved Signaling

September 21, 2023

Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial condition. Forward-looking statements include but are not limited to statements based on current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results and expected timing thereof, our plans to develop and commercialize gedatolisib, our first internally developed drug candidate, and the anticipated market opportunity at that time, our plans to research, discover and develop additional product candidates, our planned milestones and timing of achieving such milestones, the scope, protocol, and costs of our clinical development program and upcoming clinical trials for gedatolisib, including but not limited to our VIKTORIA-1 Phase 3 clinical trial and our Phase 1b/2 CELC-G-201 clinical trial, the expected results of VIKTORIA-1 and CELC-G-201, including but not limited to the anticipated efficacy of gedatolisib in combination with fulvestrant and with or without palbociclib, the anticipated efficacy of gedatolisib in combination with darolutamide, the expected timing of funding of tranches under the Company's debt financing facility, any potential benefits resulting from Breakthrough Therapy designation for gedatolisib, and other expectations with respect to Celcuity's lead product candidate, gedatolisib, our beliefs related to the perceived advantages of our CELsignia tests compared to traditional molecular or other diagnostic tests and its CELsignia platform. Words such as, but not limited to, "may," "will," "would," "should," "could," "look forward to," "believe," "predict," "expect," "anticipate," "intend," "continue", "ongoing," "target," "goal," "plan," "potential," or "estimate," and similar expressions or words, identify forward-looking statements.

Any forward-looking statements in this presentation are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this presentation, including, without limitation, risks relating to: (i) unforeseen delays in clinical trial enrollment or other activities that may affect the timing and success of our ongoing gedatolisib and CELsignia trials, (ii) the fact that preliminary data from a clinical study may not be predictive of the final results of such study or the results of other ongoing or future studies, (iii) unforeseen challenges in developing and continuing partnership opportunities with pharmaceutical companies, (iv) our ability to obtain and maintain FDA approval to commercialize gedatolisib, and the market acceptance of a commercialized product, (v) our ability to raise additional capital for further product development and other activities, (vi) the development of products or services competitive with our products, including without limitation, other effective drug candidates, diagnostic tests and treatment options, (vii) our dependence on intellectual property licenses and other third-party relationships, and (viii) uncertainties and assumptions regarding the impact of macro-economic conditions and global risks, such as the COVID-19 pandemic or a government shutdown, on our business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. In our reports and filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2022, we present more information about the risks and uncertainties applicable to our business. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

The information in this presentation does not provide full disclosure of all material facts relating to Celcuity or its securities. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities.

2

Celcuity Leadership Team and External Speakers Participating Today

Celcuity Participants

External Key Opinion Leaders

Brian Sullivan	Lance Laing, PhD	Igor Gorbatchevsky, MD		Sara Hurvitz, MD	Karim Fizazi, MD, PhD
Chief Executive Officer	Chief Scientific Officer	Chief Medical Officer		Professor of Medicine	Professor of Medicine
Co-Founder	Co-Founder			Head, Division of Hematology & Oncology	GETUG President
				Sr. Vice President, UW Medicine,	Head, GU Group,
				Fred Hutch Cancer Center	Institute Gustav Roussy
					University of Paris Saclay

3

Agenda

Topic	Session	Presenter
	Overview of Gedatolisib's Potential	Brian Sullivan
	Importance of PI3K/mTOR as an Anti-Cancer Target	Lance Laing, PhD
Scientific Overview	Gedatolisib Differentiation - Nonclinical	Lance Laing, PhD
	Gedatolisib PK and Safety Overview	Igor Gorbatchevsky, MD
Prostate Cancer	KOL Presentation: 2L SOC and PI3K/mTOR in Prostate Cancer	Karim Fizazi, MD, PhD
Gedatolisib for Prostate Cancer	Igor Gorbatchevsky, MD
Breast Cancer	KOL Presentation: SOC and Future Landscape in HR+/HER2- ABC	Sara Hurvitz, MD
Gedatolisib for Breast Cancer	Igor Gorbatchevsky, MD

Wrap-up

Q&A

Brian Sullivan

4

Introduction and

Overview

Brian Sullivan

CEO and Co-Founder

5